Sex-based differential regulation of oxidative stress in the vasculature by nitric oxide

Rommel C. Morales, Edward S.M. Bahnsen, George E. Havelka, Nadiezha Cantu-Medellin, Eric E. Kelley, Melina R. Kibbe

Division of Vascular Surgery, Northwestern University, Chicago, IL, USA
Simpson Querrey Institute for BioNanotechnology, Northwestern University, Chicago, IL, USA
Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA
Jesse Brown Veterans Affairs Medical Center, Chicago, IL, USA

**Article history:**
Received 29 December 2014
Received in revised form 8 January 2015
Accepted 12 January 2015
Available online 13 January 2015

**Abstract**

**Background:** Nitric oxide (NO) is more effective at inhibiting neointimal hyperplasia following arterial injury in male versus female rodents, though the etiology is unclear. Given that superoxide (O$_2^-$) regulates cellular proliferation, and NO regulates superoxide dismutase-1 (SOD-1) in the vasculature, we hypothesized that NO differentially regulates SOD-1 based on sex.

**Materials and methods:** Male and female vascular smooth muscle cells (VSMC) were harvested from the aortae of Sprague-Dawley rats. O$_2^-$ levels were quantified by electron paramagnetic resonance (EPR) and HPLC. sod-1 gene expression was assayed by qPCR. SOD-1, SOD-2, and catalase protein levels were detected by Western blot. SOD-1 activity was measured via colorimetric assay. The rat carotid artery injury model was performed on Sprague-Dawley rats. NO treatment and SOD-1 protein levels were examined by Western blot.

**Results:** In vitro, male VSMC have higher O$_2^-$ levels and lower SOD-1 activity at baseline compared to female VSMC (P < 0.05). NO decreased O$_2^-$ levels and increased SOD-1 activity in male (P < 0.05) but not female VSMC. NO also increased sod-1 gene expression and SOD-1 protein levels in male (P < 0.05) but not female VSMC. In vivo, SOD-1 levels were 3.7-fold higher in female versus male carotid arteries at baseline. After injury, SOD-1 levels decreased in both sexes, but NO increased SOD-1 levels 3-fold above controls in males, but returned to baseline in females.

**Conclusions:** Our results provide evidence that regulation of the redox environment at baseline and following exposure to NO is sex-dependent in the vasculature. These data suggest that sex-based differential redox regulation may be one mechanism by which NO is more effective at inhibiting neointimal hyperplasia in male versus female rodents.

Published by Elsevier B.V.

**Keywords:** Neointimal hyperplasia, Superoxide, Nitric oxide, Vascular, Sex differences

**Introduction**

Neointimal hyperplasia limits the long-term durability of vascular interventions such as balloon angioplasty, stenting, endarterectomy, and bypass grafting. Current FDA approved drug eluting stents, designed to prevent the development of neointimal hyperplasia, deliver derivatives of two different classes of drugs (i.e., rapamycin and paclitaxel), both of which indiscriminately inhibit all cellular proliferation, including endothelial cell proliferation. Thus, there is a great need to develop novel therapies that effectively prevent neointimal hyperplasia while also promoting vascular healing. Nitric oxide (NO) is one such drug that possesses many different vasoprotective properties. NO is a small gaseous molecule that is known to inhibit platelet adherence and aggregation, mitigate leukocyte chemotaxis, and prevent vascular smooth muscle cell (VSMC) and adventitial fibroblast proliferation and migration [1-9]. Simultaneously, NO stimulates endothelial cell proliferation and prevents endothelial cell apoptosis [10,11]. Our laboratory and others, have demonstrated the beneficial effect of NO delivery to the vasculature to prevent neointimal hyperplasia in various different small and large animal models of arterial injury and bypass grafting [12-20]. However, our laboratory also demonstrated that NO has differential efficacy at inhibiting neointimal hyperplasia based on sex and hormone status [21]. The etiology for this difference, with NO being more effective at inhibiting neointimal hyperplasia in males compared to females, and in hormonally intact versus castrated
animals, remains unclear.

One possible explanation may reside in the regulation of oxidative stress between the sexes. Indeed, Vassalle et al. demonstrated differing levels of oxidative stress between men and postmenopausal women, with and without coronary artery disease (CAD). While postmenopausal females with CAD exhibited greater oxidative stress compared to men, they presented with less severe CAD [22]. Reactive oxygen species (ROS) have been found to extensively contribute to the severity of vascular disease and subsequent formation of neointimal hyperplasia [23–25]. Specifically, superoxide (O$_2^*$−), one of the main ROS, has been shown to be elevated after vascular injury, resulting in the formation of neointimal hyperplasia through increased proliferation and migration of VSMC and adventitial fibroblasts [26–28]. Superoxide dismutases, modulate this response through dismutation of O$_2^*$− into oxygen and hydrogen peroxide, with the latter being enzymatically converted to water by catalase or other antioxidant peroxidases [29,30]. *NO can readily react with O$_2^*$− to form peroxynitrite, which can have detrimental effects in the vasculature. Our laboratory recently demonstrated that *NO regulates O$_2^*$− levels in a cell-specific manner in the vasculature through modulating SOD-1 levels [31]. Thus, given the role of O$_2^*$− in stimulating VSMC proliferation and migration and the role of *NO in modulating neointimal hyperplasia and SOD-1, we hypothesize that *NO differentially regulates SOD-1 levels based on sex. Here, we investigate the effect of *NO on O$_2^*$− generation, sod-1 gene expression, SOD-1 protein levels, and SOD activity in vitro and in vivo in male and female rodent models.

Materials and methods

*NO-releasing donor

1-[(N-(2-aminoethyl)-N-(2-ammonioethyl)amino)diazen-1-ium-1,2-diolato (DETA/NO) and disodium 1-[(2-carboxylato)pyrrolidine-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO) were supplied by Dr. Larry Keefer (National Cancer Institute). Both DETA/NO and PROLI/NO are diazeniumdiolate *NO donors that release 2 mols of *NO per mole of compound at a predictable rate under physiologic conditions of pH 7 and temperature 37 °C [32]. Given that the duration of the in vitro experiments were up to 24 h, we used DETA/NO for these experiments since it has a half-life of 20 h. PROLI/NO was used for all animal studies given our prior work demonstrating superior efficacy of PROLI/NO in this animal model compared to other diazeniumdiolate *NO donors [17,19,21,31].

Rat carotid artery injury model

All animal procedures were performed in accordance with principles outlined in the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publication 85-23, 1996) and approved by the Northwestern University Animal Care and Use Committee. Adult male and female Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing between 250–400 g were used for the study. Treatment groups included control, injury, and injury + *NO (n = 5 rats/treatment group). Rats were anesthetized with inhaled isoflurane (0.5–2%), with subcutaneous atropine administration (0.1 mg/kg) to minimize airway secretions. The right common carotid artery for each rat served as the control group. Following sterile preparation, a midline neck incision was made. The left common, internal, and external carotid arteries were dissected, followed by occlusion of the internal and common carotid arteries. A No. 2 French arterial embolectomy catheter (Edwards Lifesciences, Irvine, CA) was inserted into the external carotid artery and advanced into the common carotid artery. The balloon was inflated to a pressure of 5 atm for 5 min to cause uniform injury. After the balloon was deflated and removed, the external carotid artery was ligated and blood flow restored. For the injury + *NO group, 10 mg of PROLI/NO was applied evenly to the external surface of the common carotid artery after balloon injury, as previously described [17,19,21,31]. Following injury and treatment, neck incisions were closed. Rats were sacrificed 3 days after treatment to harvest carotid arteries. Arteries within treatment groups were pooled, frozen in liquid nitrogen, powdered with mortar and pestle, and homogenized in 20 mM Tris (pH 7.4) with 1 μM phenylmethylsulfonyl fluoride, 1 μM leupeptin, and 1 μM sodium orthovanadate (Sigma, St. Louis, MO). Western blot analysis was performed as described below.

Cell culture

VSMC were harvested from the aortae of male and female Sprague-Dawley rats (Harlan) via methods as described by Gunther et al. [33] Male and female VSMC were confirmed via PCR (Supplementary Fig. 1) using SRY and GAPDH primers (IDT, Coralville, IA). Cells were maintained in media containing equal volumes of Ham’s F12 and Dulbecco’s modified Eagle’s medium – low glucose (DMEM) (Invitrogen, Carlsbad, CA), complemented with 100 units/mL penicillin (Corning, Corning, NY), 100 μg/mL streptomycin (Corning), 4 mM l-glutamine (Corning), and 10% fetal bovine serum (FBS) (Invitrogen). Cells were incubated at 37 °C with 5% CO₂. To synchronize cells prior to DETA/NO treatment, cells were exposed to media lacking FBS for 24 h at 37 °C with 5% CO₂. VSMC used in this study were between passage 3 and 9.

EPR analysis

VSMC were plated on 100-mm dishes and allowed to attach overnight. Cells were serum starved for 24 h and exposed to DETA/NO (0.5–10 mM), pegylated (PEG)-SOD (50 U), or control media for 24 h. PEG-SOD was used as a control to ensure the signal measured was O$_2^*$− dependent. Cells were then washed with cold PBS, incubated with the cell-permeable spin probe, 1-hydroxy-3-methoxy-carbonyl-2,2,5,5-tetramethyipyrrolidine (CMH) (Enzo Life Sciences, Ann Arbor, MI) for 30 min, and subsequently analyzed in a temperature- and O$_2$-controlled Bruker EPR (Milwaukee, WI). The intensity of the first peak of the *CM radical spectrum was quantified. EPR signal intensity was normalized per mg of protein. All buffers contained 25 μM deferoxamine and were treated with Chelex resin from Biorad (Hercules, CA) to minimize deleterious effects of possible contaminating metals.

2-Hydroxyethidium analysis

VSMC were plated on 100-mm dishes and were incubated overnight to facilitate attachment. After cells reached 80% confluence, VSMC were exposed to DETA/NO (0.5–10 mM), pegylated PEG-SOD (50 U), or control media for 24 h.PEG-SOD was used as a control to ensure the changes measured were O$_2^*$− dependent. After 24 h of exposure to the various experimental conditions, VSMC were exposed to 10 μM of dihydroethidium (DHE) (Invitrogen) in the dark for 30 min. Subsequently, cells were washed with cold PBS, scraped, collected, protected from light, and stored at −80 °C. O$_2^*$− levels were determined by quantifying the levels of 2-hydroxyethidium (2-OH-E) by HPLC with electrochemical detection according to Zielonka et al. [35]. The results were expressed as pmols of O$_2^*$− per mg of protein in total cell lysate.
Western blot analysis

After 24 h of exposure to the various experimental conditions, VSMC were washed with cold PBS, scraped, and resuspended in 20 mM Tris at pH 7.4, supplemented with 1 μM phenylmethylsulfonyl fluoride, 1 μM leupeptin, and 1 μM sodium orthovanadate (Sigma). Protein concentrations were determined via a bicinchoninic acid protein assay per manufacturer’s instructions (Pierce, Rockford, IL). Equivalent protein amounts of each cell lysate were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 13% separating gels and transferred to nitrocellulose membranes (Schleicher & Shuell, Keene, NH). Membranes were probed with antibodies raised against either β-actin, SOD-1, SOD-2, or catalase for 1 h at room temperature or overnight at 4 °C, followed by hybridization with goat anti-rabbit secondary antibody conjugated to HRP for 1 h at room temperature. Proteins were imaged with chemiluminescent reagents, Supersignal Substrate, and processed according to manufacturer’s instructions (Pierce). Films exposed to membranes were analyzed with ImageJ (Bio-Rad) and Ct values were exported as Excel files. Fluorescence was detected via an iQ5 optical system (Bio-Rad) and Ct values were exported as Excel files. Expression of sod-1 was calculated using GAPDH as a reference and normalized to male control.

Quantitative PCR

After either 6 or 12 h of exposure to the various experimental conditions, VSMC were washed with cold PBS, scraped, and collected. RNA was isolated from samples via RNeasy Protect Mini Kit per manufacturer’s instructions (Qiagen, Germantown, MD). RNA concentrations were determined via a Gen5 Take 3 Module per manufacturer’s instructions (BioTek, Winooski, VT). Equivalent RNA amounts were converted into cDNA via a QuantiTect Reverse Transcription Kit per manufacturer’s instructions (Qiagen). Quantitative PCR was performed via a QuantiTect SYBR Green PCR Kit using SOD-1 and GAPDH primers according to manufacturer’s instructions (Qiagen). Fluorescence was detected via an iQ5 optical system (Bio-Rad) and Ct values were exported as Excel files. Expression of sod-1 was calculated using GAPDH as a reference and normalized to male control.

SOD activity assay

SOD-1 enzyme activity on cytosolic fractions was assayed using a colorimetric kit by Cayman Chemicals (Ann Arbor, MI) according to the manufacturer’s specifications. Potassium cyanide, a SOD-1 inhibitor, was used to differentiate SOD-1 from SOD-2 activity.

Statistical analysis

Results are expressed as the mean ± standard error of the mean (SEM). Variation between sexes and treatments for O₂⁻\(^{−}\) and SOD activity measurements was analyzed using two-way ANOVA with the Student–Newman–Keuls post hoc test for pairwise comparisons. Differences between non-normally distributed variables (qPCR and protein data) were analyzed by the Wilcoxon rank sum and an ANOVA on ranks with the Dunn’s post hoc test for pairwise comparisons. All statistical analyses were performed using either SigmaPlot v10.0 (Systat Software Inc, CA, USA), or SAS (SAS Institute Inc., NC, USA). Threshold for statistical significance was assumed at \(P \leq 0.05\).

Results

\( ^\star \text{NO} \) decreases generation of O₂⁻\(^{−}\) in male, but not female VSMC.

To determine the effect of sex on O₂⁻\(^{−}\) levels, EPR signal and HPLC analysis were used to quantify O₂⁻\(^{−}\) (Fig. 1A and B). At baseline, \( ^\star \text{CM} \) EPR signal was higher in male compared to female VSMC \((P < 0.001)\), suggesting higher O₂⁻\(^{−}\) levels in male VSMC. Following exposure to DETA/NO (1 mM), the \( ^\star \text{CM} \) EPR signal in male VSMC decreased 22% compared to untreated VSMC \((P < 0.001)\), suggesting a decrease in O₂⁻\(^{−}\) levels. However, female VSMC show no significant change with increasing DETA/NO treatment \((P < 0.05)\). This interaction between sex and \( ^\star \text{NO} \)
concentration is statistically significant \((P = 0.003)\). VSMC pre-treated with PEG-SOD (50 U) also show a decrease in EPR signal, which suggests that the *CM radical signal is due to \(O_2\)^− (Fig. 1A). To further validate these \(O_2\)^− findings, the \(O_2\)^−-specific oxidation product of dihydroethidium, 2-hydroxyethidium (2-OH-E) was analyzed via HPLC (Fig. 1B), and a similar pattern emerged. At baseline, the levels of 2-OH-E were higher in male compared to female VSMC \((P = 0.002)\). \(O_2\)^− generation in male VSMC decreased by 29\% with increasing DETA/NO treatment (Fig. 1B, \(P < 0.05\)). Again, female VSMC showed no significant change with increasing DETA/NO treatment (Fig. 1B). As expected, VSMC exposed to PEG-SOD (50 U) showed a decrease in \(O_2\)^− levels. These data suggest that \(O_2\)^− levels are higher in male compared to female VSMC at baseline, but that *NO affects \(O_2\)^− levels more in male compared to female VSMC.

*NO affects SOD-1 expression levels in male, but not female VSMC in a concentration- and time-dependent manner

Given the differential \(O_2\)^− levels in male and female VSMC at baseline and following *NO exposure, sod-1 expression levels were examined via qPCR (Fig. 2). The data show a trend for females to have higher sod-1 expression at baseline (1.9 fold). However, this trend did not reach statistical significance \((Fig. 2; P = 0.07)\). On the other hand, expression of sod-1 increased with all concentrations of DETA/NO tested at 6 h in male VSMC \((Fig. 2A, P < 0.05\)). Female VSMC showed no statistically significant change in sod-1 expression with DETA/NO treatment \((Fig. 2A)\). This interaction between sex and DETA/NO treatment is statistically significant \((P=0.006)\). To explore whether the female response to *NO could be delayed, sod-1 expression was examined 12 h following exposure to DETA/NO \((1 \text{ mM})\) (Fig. 2B). While sod-1 expression increases to 2.1-fold at 6 h in male VSMC \((P < 0.05, \text{Fig. 2B})\), it was not significantly different from control at 12 h \((\text{Fig. 2B})\). However, no significant increase in expression in females occurred with DETA/NO over 12 h \((\text{Fig. 2B})\). These data suggest sod-1 gene expression in VSMC depend on sex and that *NO has differential effects on regulating sod-1 gene expression in male versus female VSMC.

*NO affects sod-1 protein levels in male, but not female VSMC

Given the differential effect on sod-1 transcription between the sexes at baseline and after DETA/NO treatment, sod-1 protein levels were assessed via Western blot analysis \((\text{Fig. 3A})\). Densitometry data of Western blots revealed that there was a trend toward higher sod-1 protein levels at baseline in female versus male VSMC, but this difference did not reach statistical significance \((P=0.4)\). When analyzed by sex, DETA/NO increased sod-1 levels 1.9-fold in male VSMC compared to control \((P < 0.05, \text{Fig. 3B})\). SOD-1 protein levels did not change in female VSMC following exposure to DETA/NO \((\text{Fig. 3B})\). In order to determine the relative contribution of SOD-1 in influencing these changes in oxidative stress, SOD-2 and catalase protein levels were also examined. SOD-2 \((\text{Fig. 3C})\) and catalase \((\text{Fig. 3D})\) protein levels were not different at baseline between the sexes, nor did they change significantly with increasing DETA/NO treatment in either sex. These data suggest that the action of *NO in regulating \(O_2\)^− levels in VSMC is attributed mainly to changes in SOD-1 protein levels in male VSMC.

*NO affects SOD activity in male, but not female VSMC

Given the differences in \(O_2\)^− levels, sod-1 gene expression, and sod-1 protein levels following *NO treatment between the sexes, we assessed SOD activity in both sexes at baseline and after *NO exposure and normalized the data to male control for comparisons between the sexes \((\text{Fig. 4})\). Congruent with our previous findings in \(O_2\)^− levels and sod-1 gene expression, female VSMC had 2.1 fold higher SOD − 1 activity at baseline compared to male VSMC \((P < 0.001)\). Following treatment with DETA/NO, SOD activity increased 2.7-fold in male VSMC \((P < 0.001 \text{ vs. male control, \text{Fig. 4})}\). There was no DETA/NO -induced change in SOD-1 activity in female VSMC. This interaction between sex and *NO concentration was statistically significant \((P = 0.019)\). These data suggest that SOD activity in VSMC is based on sex and that *NO modulates SOD activity more in male compared to female VSMC.

*NO differentially increases sod-1 protein levels in male and female carotid arteries after injury

To determine if sod-1 levels are effected by *NO in vivo, sod-1 protein levels were assessed via Western blot analysis from lysates isolated from carotid arteries that were balloon injured or injured and exposed to *NO treatment \((\text{Fig. 5})\). At baseline, female carotid arteries exhibited higher sod-1 protein levels compared to male

---

**Fig. 2.** Nitric oxide (*NO) increases sod-1 gene expression in male, but not female, VSMC. (A) Quantitative PCR showed sod-1 gene expression is higher in females then males at baseline, and increases in male but not in female VSMC with DETA/NO treatment at 6 h \((?P < 0.05 \text{ vs. control, } N=3 \text{ for males and } N=4 \text{ for females})\). (B) Quantitative PCR showed sod-1 gene expression time course. In male VSMC treated with DETA/NO sod-1 increases at 6 h and starts to return to baseline by 12 h \((?P < 0.05 \text{ vs. control, } N=8 \text{ for controls, } N=3 \text{ for 6 and 12 h})\). In female VSMC, DETA/NO treatment has no significant effect at 6 and 12 h \((N=7 \text{ for control, } N=4 \text{ for 6 h, and } N=3 \text{ for 12 h})\).
SOD-1 protein levels decreased 3 days after balloon injury in both sexes as compared to control arteries. Treatment with DETA/NO increased SOD-1 levels following arterial injury in both sexes compared to injury alone (Fig. 5A).

Densitometry data of Western blots were normalized to β-actin and male control to compare data between the sexes (Fig. 5B). Female carotid arteries had 3.7-fold higher SOD-1 protein levels at baseline compared to male carotid arteries. Following arterial injury, SOD-1 protein levels decreased similarly in both sexes (69% vs. 68%, respectively). Following arterial injury and DETA/NO exposure, SOD-1 protein levels increased 3.0-fold higher then control levels in males, but returned to baseline levels in females (Fig. 5B). These data provide further evidence that SOD-1 levels differ at baseline between the sexes, and that DETA/NO exerts a differential effect on male and female SOD-1 regulation after injury in vivo.

Discussion

Our present study shows that significant differences exist in $O_2^-$ levels and SOD activity between male and female VSMC and carotid arteries at baseline. We also show that DETA/NO exposure affects the redox environment differently between the sexes in VSMC and carotid arteries. At baseline, $O_2^-$ levels were higher in male VSMC and this corresponded to lower SOD activity, as compared to female VSMC. Basal SOD-1 protein levels and sod-1 gene expression, both showed a trend to be higher in female than males. Following exposure to DETA/NO, $O_2^-$ levels decreased in male VSMC and were associated with corresponding increases in sod-1 gene expression, SOD-1 protein levels, and SOD activity. DETA/NO caused no such changes in female VSMC. A similar pattern was also observed in carotid arteries following arterial injury and DETA/NO exposure.
oxidative stress. Most importantly, Strehlow et al. showed that estradiol can directly regulate the subunits of NADPH oxidase, an enzyme that produces ROS in endothelial cells and VSMC with a low estrogen level [39]. Stirone et al. showed that estrogen can increase eNOS gene expression and hydrobiopterin, preventing eNOS uncoupling and ROS generation by increasing the availability of tetrahydrobiopterin, consistent with the research showing that premenopausal women have lower ROS levels than postmenopausal women [36,37]. It has also been shown that overexpression of SOD-1 limits the development of neointimal hyperplasia in vivo [36,37].

This sex-based differential regulation of SOD-1 has implications in pro-proliferative states such as neointimal hyperplasia. SOD has been shown to decrease VSMC proliferation and migration in vitro [36,37]. It has also been shown that overexpression of SOD-1 limits the development of neointimal hyperplasia in vivo. Kuo et al. showed that arteries in which SOD-1 was overexpressed developed 50% less neointimal hyperplasia compared to controls [29]. Muscoli et al. delivered a SOD mimic to rats to inhibit balloon-induced neointimal hyperplasia [30]. On the other hand, Hogg et al. showed that male VSMC proliferated and migrated more than female VSMCs, and that NO inhibited proliferation and migration more effectively in male VSMCs compared to female cells [21]. Thus, given that our laboratory that NO specifically increases SOD-1 levels both in vitro and in vivo, our current findings on the sex-based regulation of SOD-1 following exposure to NO may account for the sex-based difference in the inhibition of neointimal hyperplasia by NO [21,31].

Interestingly, we observed differences in basal levels of O2•− and SOD-1 activity between the sexes, with higher SOD activity in females and corresponding lower O2•− levels. These data are consistent with the research showing that premenopausal women develop less CAD and have lower cardiovascular mortality [38]. In addition, several investigations are supportive of our overall finding. For example, Lam et al. showed that estrogen can directly impact ROS generation by increasing the availability of tetrahydrobiopterin, preventing eNOS uncoupling and ROS generation [39]. Stirene et al. showed that estrogen can increase eNOS gene expression while McNeill et al. demonstrated increased eNOS protein levels in endothelial cells and VSMC with 17β estradiol treatment [40,41]. Arias-Loza et al. demonstrated that estrogen can directly regulate the subunits of NAPDH oxidase, an enzyme responsible for ROS production, resulting in additional control of oxidative stress [42]. Most importantly, Strehlow et al. showed that 17β-estradiol specifically upregulates SOD expression and activity, resulting in the inhibition of ROS levels in VSMC [43]. Thus, our study demonstrating a sex-based differential in basal oxidative stress is supported by existing literature on the effects of estrogen. However, our study is distinct because we specifically link sex to differential regulation of the redox environment at baseline, following arterial injury, and following treatment with NO, and the severity of neointimal hyperplasia observed in vivo.

Bahnson et al. demonstrated the importance of NO-dependent regulation of SOD-1 in inhibiting VSMC proliferation through modulation of O2•− levels [31]. DHE fluorescence serves as a general indicator for O2•− levels and has been previously used to qualify and quantitate the extent of reactive oxidative species. Similar to our findings, Wedgwood et al. reported a concurrent 80% reduction in DHE fluorescence in VSMC exposed to NO [44]. However, Wedgwood et al. analyzed total DHE fluorescence which is not a specific measurement of O2•−. Though we report smaller decreases in O2•− levels, our results are based on HPLC detection of 2-hydroxyethidium, the only validated, specific method for O2•− measurement [45]. In addition, Wedgwood et al. assessed DHE fluorescence with the NO donor still present in the cells [44]. As NO readily reacts with O2•−, the reduction in DHE fluorescence could be confounded by O2•− scavenging by NO, rather than be a consequence of redox protein regulation upon treatment. To account for this in our experimental design, the NO donor was completely removed and the cells thoroughly washed before exposing the cells to DHE. In doing so, the decrease in O2•− in male VSMC is attributed to an increase in SOD-1 levels and activity, as opposed to a direct reaction of NO with O2•−. Nevertheless, a direct reaction between NO and O2•− while the NO donor is present cannot be discounted. Moreover, Bahnson et al. have reported increased nitration in male VSMC treated with DETA/NO [31].

Our study is not without limitations. Firstly, in our O2•− measurement experiments, we used PEG-SOD as a control. We showed that, as expected PEG-SOD decreased O2•− levels in males. However, PEG-SOD failed to further decrease the O2•− signal in females. Moreover, basal O2•− levels in females were as low as the levels in males treated with exogenous PEG-SOD. A possibility for this phenomenon is that baseline levels of the O2•− are already so low that the PEG-SOD added is not enough to cause a further reduction. Secondly, we analyzed the redox environment and the O2•− – SOD relationship using a variety of techniques. Whereas SOD-1 activity, O2•− levels, and sod-1 gene expression showed a statistically significant interaction between sex and NO, SOD-1 protein levels did not. This is probably due to the sample size used in the Western blot analysis and its intrinsic semi-quantitative nature, which may not have provided sufficient statistical power. When analyzed separately, we found that SOD-1 protein levels are higher upon DETA/NO treatment, consistent with previous...
findings by Bahnsen et al. [31] This effect was not observed in females. In this work, we show significant changes in gene expression, activity, and O2*− levels in male VSMC but not in female VSMC with a significant interaction between sex and *NO variables. In addition, we focused primarily on an analysis of the impact of *NO on SOD-1; therefore, the interplay between additional protein factors as well as the dynamics between other cell types (e.g., endothelial cells, adventitial fibroblasts) was excluded from this study. However, we have previously shown that *NO treatment has no effect on SOD-1 in adventitial fibroblasts and endothelial cells from male rats [31]. While SOD-2 and catalase were close to reality.

Can be developed for both sexes, bring personalized medicine neointimal hyperplasia based on sex [21]. By furthering our understanding of SOD-1 levels and neointimal hyperplasia, this work was supported by the Women’s Health Research Institute and the Society for Vascular Surgery Foundation. Funding sources had no influence in the conduct of the research or preparation of the article. The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.

Conflicts of interest

This work was supported by the Women’s Health Research Institute and the Society for Vascular Surgery Foundation. Funding sources had no influence in the conduct of the research or preparation of the article. The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.

Acknowledgements

The authors would like to thank the Simpson Querrey Institute for BioNanotechnology for usage of their facilities, Dr. Nick Tishlis and Ms. Lynnette Dangerfield for editorial assistance, and Ms. Irene B. Helenowski for her statistical expertise.

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.redox.2015.01.007.

References

[1] S.S. Ahanchi, N.D. Tishlis, M.R. Kibbe, The role of nitric oxide in the pathophysiology of intimal hyperplasia, Journal of Vascular Surgery 45 (Suppl. A) (2007) A64–A73. http://dx.doi.org/10.1016/j.jvs.2007.02.027 15744026.

[2] M.R. Kibbe, J. Li, S. Nie, S.C. Watkins, A. Lizonova, I. Kovesdi, R.L. Simmons, T. R. Billiar, E. Tzeng, Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate, Journal of Vascular Surgery 31 (6) (2000) 1214–1228. http://dx.doi.org/10.1067/mva.2000.105006 10842159.

[3] R.F. Furchgott, J.V. Zawadzki, The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine, Nature 288 (5789) (1980) 373–376. http://dx.doi.org/10.1038/288373a0 6253831.

[4] R.M. Palmer, A.C. Ferrigno, M. Moncada, Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor, Nature 327 (6122) (1987) 524–526. http://dx.doi.org/10.1038/327524a0 3495737.

[5] M.W. Radomski, R.M. Palmer, S. Moncada, The role of nitric oxide and CO in platelet adhesion to vascular endothelium, Biochemical and Biophysical Research Communications 148 (3) (1987) 1482–1489. http://dx.doi.org/10.1016/S0006-291X(87)80299-1 2825688.

[6] P. Kubés, M. Suzuki, D.N. Granger, Nitric oxide: an endogenous modulator of leukocyte function, Proceedings of the National Academy of Sciences USA 88 (11) (1991) 4651–4655. http://dx.doi.org/10.1073/pnas.88.11.4651 1675786.

[7] U.C. Garg, A. Hassid, Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/c 3T3 fibroblasts by a cAMP-independent mechanism, Biochemical and Biophysical Research Communications 171 (1) (1990) 474–479. http://dx.doi.org/10.1016/0006-291X(90)91417-Q 1697465.

[8] M.J. Pollman, T. Yamada, M. Horiiuchi, G.H. Gibbons, Vasoactive substances regulate smooth vascular muscle cell apoptosis, countervailing influences of nitric oxide and angiotensin II, Circulation Research 79 (4) (1996) 748–756. http://dx.doi.org/10.1161/01.RES.79.4.748 8814198.

[9] P.J. Guo, M.M. Panday, P.M. Consigny, A.M. Lefer, Mechanisms of vascular preservation by a novel NO donor following rat carotid artery intimal injury, American Journal of Physiology 269 (3 Pt 2) (1995) H1122–H1131 7573510.

[10] E. Tzeng, Y.M. Kim, B.R. Pitt, A. Lizonova, I. Kovesdi, T.R. Billiar, Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis, Surgery 122 (1997) 255–263. http://dx.doi.org/10.1016/S0039-6060(97)00136-9 9281360.

[11] M. Ziche, L. Morbidielli, E. Masini, S. Amerini, H.J. Granger, C.A. Maggi, P. Peppetti, F. Ledda, Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P, Journal of Clinical Investigation 94 (5) (1994) 2036–2044. http://dx.doi.org/10.1172/JCI117557 7525653.

[12] A. Chaux, X.M. Ruan, M.C. Fishbein, O. Ouyang, S. Kaul, J.A. Pass, J.M. Matloff, Percutaneous delivery of a nitric oxide donor inhibits neointimal hyperplasia, Surgery 122 (1997) 2630–2638. http://dx.doi.org/10.1016/S0039-1447(97)80327-8 8765728.

[13] J.S. Lee, C. Adrie, H.J. Jacob, D.J. Roberts, W.M. Zapol, K.D. Bloch, Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury, Circulation Research 78 (2) (1996) 337–342. http://dx.doi.org/10.1161/01.RES.78.2.337 8157078.

[14] C.G. Pearce, S.F. Najjar, M.R. Kapadia, J. Murat, J. Eng, B. Lyle, O.O. Aalami, Q. Jiang, J.A. Hrabie, J.E. Saavedra, L.K. Kefer, M.R. Kibbe, Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia, Free Radical Biology and Medicine 44 (1) (2008) 73–81. http://dx.doi.org/10.1016/j.freeradbiomed.2007.09.010 18045549.

[15] L.L. Shears, M.R. Kibbe, A.D. Murdock, T.R. Billiar, A. Lizonova, I. Kovesdi, S. C. Watkins, E. Tzeng, Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo, Journal of American College of Surgeons 187(3) (1998) 295–306. http://dx.doi.org/10.1016/S0002-9343(98)90230-3 10741131.

[16] A.K. Vavara, G.E. Havelka, J. Martinez, V.R. Lee, B. Fu, Q. Jiang, L.K. Kefer, M. R. Kibbe, Insights into the effect of nitric oxide and its metabolites nitrite and nitrate at inhibiting neointimal hyperplasia, Nitric Oxide 25 (1) (2011) 22–30. http://dx.doi.org/10.1016/j.niox.2011.04.013 21554972.

[17] H.E. Von der Leyen, G.H. Gibbons, R. Morek, J.P. Lewis, L. Zhang, M. Nakajima, Y. Kaiseda, J.P. Coole, V.J. Daue, Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene, Proceedings of the National Academy of Sciences USA 92 (4) (1995) 1137–1141. http://dx.doi.org/10.1073/pnas.92.4.1137 7573510.

[18] M.E. Hogg, V.N. Varu, A.K. Vavara, D.A. Popovich, M.N. Banerjee, J. Martinez, Q. Jiang, J.E. Saavedra, L.K. Kefer, M.R. Kibbe, Effect of nitric oxide on neointimal hyperplasia based on sex and hormone status, Free Radical Biology and Medicine 50 (9) (2011) 1065–1074. http://dx.doi.org/10.1016/j.freeradbiomed.2011.01.016 21256099.

[19] C. Vassalle, R. Sciarinno, S. Bianchi, D. Battaglia, A. Mercuri, S. Maffeï, Sex-related differences in association of oxidative stress status with coronary artery disease, Fertility and Sterility 102 (2) (2012) 414–419. http://dx.doi.org/10.1016/j.fertnstert.2011.04.022 22196713.

[20] C.M. Jacobson, H.M. Dourron, J. Liu, O.A. Carretero, D.J. Reddy, T. Andrzejewski, P. Jagano, Novel NADPH oxidase inhibitor suppresses angioply-induced...
superoxide and neointimal hyperplasia of rat carotid artery, Circulation Research 92 (6) (2003) 637–643. http://dx.doi.org/10.1161/01.RES.0000063423.94654.AA 12509967.

[24] H.P. Souza, L.C. Souza, V.M. Anastacio, A.C. Pereira, M.L. Junqueira, J.E. Krieger, P.L. da Luz, O. Augusto, F.R. Laurindo, Vascular oxidant stress early after balloon injury: evidence for increased NAPDH oxidoreductase activity, Free Radical Biology and Medicine 28 (8) (2000) 1232–1242. http://dx.doi.org/10.1016/S0891-5849(00)00240-9 10885453.

[25] L.C. Azevedo, M.A. Pedro, L.C. Souza, H.P. de Souza, M. Janiszewski, P.L. da Luz, F.R. Laurindo, Oxidative stress as a signaling mechanism of the vascular response to injury: the redox hypothesis of restenosis, Cardiovascular Research 47 (3) (2000) 436–445. http://dx.doi.org/10.1016/S0008-6363(00)00591-2 10963717.

[26] C.-C. Yin, K.-T. Huang, H2O2 but not O2− elevated by oxidized LDL enhances human aortic smooth muscle cell proliferation, Journal of Biomedicine Science 14 (2) (2007) 245–254. http://dx.doi.org/10.1142/s111373-006-9132-4 17124666.

[27] H.Y. Jeong, H.Y. Jeong, C.D. Kim, p22phox-derived superoxide mediates enhanced proliferative capacity of diabetic vascular smooth muscle cells, Diabetes Research and Clinical Practice 64 (1) (2004) 1–10. http://dx.doi.org/10.1016/j.diabres.2003.10.004 15036821.

[28] M.J. Haurani, P.J. Pagano, Adventitial fibroblast reactive oxygen species as autocrine and paracrine mediators of remodeling: bellwether for vascular disease? Cardiovascular Research 75 (4) (2007) 679–689. http://dx.doi.org/10.1016/j.cardiores.2007.06.016 17089510.

[29] M.D. Kuo, I.J. Bright, D.S. Wang, P. Ghafouri, E. Yuksel, P.R. Hilfinger, D.N. Miniati, M.D. Dale, Local resistance to oxidative stress by overexpression of copper–zinc superoxide dismutase limits neointimal formation after angioplasty, Journal of Endovascular Therapy 11 (6) (2004) 585–594. http://dx.doi.org/10.1583/04-1310.1 15615548.

[30] C. Muscoli, I. Sacco, W. Alexee, E. Palma, R. Nisticò, N. Costa, F. Clementi, D. Rotitro, F. Romeo, D. Salvemini, J. Mehta, V. Mollace, The protective effect of superoxide dismutase mimetic M40401 on balloon injury-related neointima formation: role of the lectin-like oxidized low-density lipoprotein receptor-1, Journal of Pharmacology and Experimental Therapeutics 311 (1) (2004) 44–50. http://dx.doi.org/10.1124/jpet.103.068205 15220533.

[31] E.S.M. Bahnson, L.K. Keefer, Progress toward clinical application of the nitric oxide-releasing E.S.M. Bahnson, N. Koo, N. Cantu-Medellin, A.Y. Tsui, G.E. Havelka, J. Hirschberg, T. Radovits, S. Korkmaz, S. Loganathan, S. Zöllner, B. Seidel, S. Pili, E. Barnucz, B. Merkely, M. Karck, C. Szabó, Combined superoxide dismutase mimetic and peroxynitrite scavenger protects against neointima formation after endarterectomy in association with decreased proliferation and nitro-oxidative stress, European Journal of Vascular and Endovascular Surgery 40 (2) (2010) 108–175. http://dx.doi.org/10.1016/j.ejvs.2010.03.024 20434373.

[32] K.-N. Wang, N. Shi, S.-Y. Chen, Manganese superoxide dismutase inhibits neointima formation through attenuation of migration and proliferation of vascular smooth muscle cells, Free Radical Biology and Medicine 52 (1) (2012) 173–181. http://dx.doi.org/10.1016/j.freeradbiomed.2011.04.042 22062629.

[33] E. Barrett-Connor, T.L. Bush, Estrogen and coronary heart disease in women, Journal American Medical Association 265 (14) (1991) 1861–1867. http://dx.doi.org/10.1001/jama.265.14.1861 2005736.

[34] K.-K. Lam, Y.-M. Lee, G. Hsiao, S.-Y. Chen, M.-H. Yen, Estrogen therapy replenishes vascular tetrahydrobiopterin and reduces oxidative stress in ovariectomized rats, Menopause 13 (2) (2006) 254–302. http://dx.doi.org/10.1097/01.gme.0000182806.99137.5e 16645543.

[35] A.M. McNeill, N. Kim, S.P. Duckles, D.N. Krause, H.A. Kontos, Chronic estrogen treatment increases levels of endothelial nitric oxide synthase protein in rat cerebral microvessels, Stroke 30 (10) (1999) 2186–2190. http://dx.doi.org/10.1016/S0039-6109(99)00626-5 10512927.

[36] C. Stirone, Y. Chu, L. Sunday, S.P. Duckles, D.N. Krause, 17 Beta-estradiol increases endothelial nitric oxide synthase mRNA copy number in cerebral blood vessels: quantification by real-time polymerase chain reaction, European Journal of Pharmacology 478 (1) (2005) 35–38. http://dx.doi.org/10.1016/j.ejphar.2003.08.017 14551582.

[37] P.-A. Arias-Loza, M. Muehfelder, T. Pelzer, Estrogen and estrogen receptors in cardiovascular oxidative stress, Pluggers Archives 465 (5) (2013) 739–746. http://dx.doi.org/10.1001/jama.2013.142207.

[38] K. Srethew, S. Rotter, S. Wassmann, O. Adam, C. Grohé, K. Laufs, M. Böhm, G. Nickenig, Modulation of antioxidant enzyme expression and function by estrogen, Circulation Research 93 (2) (2003) 170–177. http://dx.doi.org/10.1161/01.RES.0000102212.16757.bk 746.

[39] S. Wedgwood, S.M. Black, Molecular mechanisms of nitric oxide-induced growth arrest and apoptosis in fetal pulmonary arterial smooth muscle cells, Nitric Oxide 9 (4) (2003) 201–210. http://dx.doi.org/10.1016/j.niox.2003.11.005 14986427.

[40] R. Michalski, B. Michalowski, A. Sikora, J. Zielonka, B. Kalyanaraman, On the use of fluorescence lifetime imaging and dihydroxyethidine to detect superoxide in intact animals and ex vivo tissues: a reassessment, Free Radical Biology and Medicine 67 (2014) 278–284. http://dx.doi.org/10.1016/j.freeradbiomed.2013.10.016 24200598.